Management of Hypokalemic Periodic Paralysis
For acute attacks of hypokalemic periodic paralysis, administer oral potassium chloride at 0.5-1.0 mEq/kg, and for long-term prophylaxis, use dichlorphenamide as first-line therapy or acetazolamide as an alternative, with potassium-sparing diuretics as additional options. 1
Acute Attack Management
Immediate Treatment
- Administer potassium chloride at 0.5-1.0 mEq/kg 1
- The oral route is strongly preferred over intravenous administration 1
- If IV administration is absolutely necessary, use mannitol as the solvent (never dextrose or saline, which can worsen the attack) 1
- Monitor cardiac rhythm continuously during potassium replacement 2
- Check serum potassium levels frequently during treatment 2
Critical Pitfall
Avoid glucose-containing solutions and high-sodium IV fluids, as these are common triggers that will exacerbate the paralysis. Carbohydrates drive potassium intracellularly and worsen the attack 1.
Supportive Care
- Ensure adequate hydration 2
- Exclude secondary causes of hypokalemia (thyrotoxicosis, renal tubular acidosis, diuretics) 2, 3
- Most patients recover completely within hours with appropriate potassium replacement 2
Long-Term Prophylactic Management
First-Line Therapy: Dichlorphenamide
Dichlorphenamide is the most effective prophylactic agent based on the highest quality randomized controlled trial evidence 4. In a study of 42 patients with hypokalemic periodic paralysis:
- Significantly reduced attack rate (P = 0.02) 4
- Significantly reduced severity-weighted attack rate (P = 0.01) 4
- 15 of 34 patients preferred dichlorphenamide over placebo 4
Alternative Prophylactic Agents
- Acetazolamide: Proven to improve muscle strength in hypokalemic periodic paralysis patients 4
- Potassium-sparing diuretics (spironolactone): Effective in reducing attack frequency 5
- These carbonic anhydrase inhibitors and potassium-sparing agents decrease both attack frequency and severity 1
Important Limitation
Note that prophylactic medications (acetazolamide, dichlorphenamide, potassium-sparing diuretics) are of little value during acute attacks—they work only for prevention 1.
Trigger Avoidance Strategy
Educate patients to avoid or prepare for these specific triggers:
- Rest after vigorous exercise: Most common trigger 6, 7
- High-carbohydrate meals: Drive potassium intracellularly 6, 1
- High sodium intake: Exacerbates attacks 1
- Cold exposure 1
- Stress and infections (including COVID-19) 7
Prophylactic potassium supplementation before known triggers can prevent attacks 1.
Safety Measures
Home Environment
Every patient should have potassium supplements, water, and a telephone at their bedside at all times, regardless of whether they are currently experiencing weakness 1. This is critical because attacks can progress rapidly and leave patients unable to reach help.
Perioperative Management
Check the patient's clinical status and potassium levels frequently during any surgical procedure 1. Anesthesia and surgical stress can precipitate attacks.
Long-Term Monitoring
Nephrology Follow-Up
Patients require regular nephrology follow-up due to the risk of developing progressive proximal myopathy, a permanent complication that can occur with chronic disease 6. The muscle weakness in hypokalemic periodic paralysis is reversible during attacks, but long-term management is essential to prevent permanent weakness 5.
Genetic Confirmation
A positive genetic test (mutations in CACNA1S or SCN4A genes) in the context of typical symptoms is the gold standard for diagnosis 1, 7. This confirms the diagnosis and enables family genetic counseling, as the condition follows autosomal dominant inheritance 6, 7.
Treatment Response
With appropriate acute treatment and prophylactic therapy, patients typically experience: